Featured Stories
ASCO 2023 - Servier’s Vorasidenib Puts The Brakes On Brain Cancer In INDIGO
Servier’s targeted therapy, vorasidenib, can effectively delay the need for more drastic treatment in patients with low-grade glioma, but increases in liver enzymes including two cases of Hy’s law have cast some shade over the INDIGO data.
ImmunoGen’s Elahere Data In Avastin-Naïve Ovarian Cancer Prompt Discussion About Earlier Use
The presenter on the MIRASOL study called the data “practice changing,” while the discussant cited Sutro’s STRO-002 as a potential option for patients with low folate receptor alpha expression.
Finance Watch: Perlmutter’s Eikon Raises $106m, In-Licenses Pipeline Programs
Private Company Edition: Former Merck R&D head Roger Perlmutter and his new team have accessed drug candidates in oncology and neurodegenerative diseases from three companies, along with new funding. Also, Carmot raised $150m in series E equity and BenchSci brought in $70m.
Asia Spotlight
Chinese Public Payer Data Show More New Drugs Get Faster Coverage
China’s Basic Medical Insurance Fund spent 7.1 times more on novel drugs in 2022 compared to 2019, according to figures disclosed by the National Healthcare Security Administration. Meanwhile, such drugs need to wait less to be eligible for reimbursement in China.
Dr Reddy’s CEO: We’re In ‘Great Dialogue’ With The Innovation Industry In China
Falling At The Start Line: Chinese Firms Face Multiple Commercial Challenges Beyond Price, Coverage
Biocon Pumps Up For Adalimumab US Debut Amid Payer ‘Steady State’
Zydus Looks To NASH Trials In Turkey, gVascepa Launch In The US
Latest News
Scrip Originals
Executives On The Move: Jubilant, Mithra And More
Recent executive moves in the industry include C-suite changes at Jubilant Pharmova and Sanofi. Meanwhile, new directors were appointed at Mithra Pharmaceuticals and Calliditas Therapeutics.
Stock Watch: Defeat Is The Mother Of Reinvention
Companies that are successful do not need to change their name, therapeutic area or product focus.
Pipeline Watch: 12 Approvals And 27 Phase III Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Executives On The Move: Oncorus, Orphazyme and More
Recent executive moves in the industry include C-suite changes at Oncorus and Gamida Cell. Meanwhile, new directors were appointed at Orphazyme and Viatris.
Interviews
From Hengrui To Moderna: Why More Biotech Companies Are Creating Swiss Hubs
An increasing number of biotech companies originating from the US and Asia are building EU headquarters in Switzerland. Scrip spoke with four key opinion leaders on the motivations behind these decisions and the role the domestic ecosystem has to play, from school systems to neutral politics and beyond.
Plotting The Path For Pharma To Maintain New-Found Trust
Trustworthiness in the pharmaceutical industry has settled since its peaks during the COVID-19 pandemic but it can move upwards again if companies assume responsibility to inform on wider issues, according to experts at Edelman.
Kanaph CEO On Surviving The Biotech Funding 'Barley Hump'
The CEO of Korean bioventure Kanaph Therapeutics, Byoung Chul Lee, talks to Scrip about the difficulties such companies are going through amid generally weak investor sentiment, as well as the company's own financing and R&D plans.
Ionis Invests For The Future In New Technologies, Manufacturing Innovation
Through partnerships with Bicycle and Metagenomi, Ionis is working on new chemistries and novel medicines. It is also expanding manufacturing capacity to enable its scientific growth.
Graphics
Executives On The Move: Jubilant, Mithra And More
Recent executive moves in the industry include C-suite changes at Jubilant Pharmova and Sanofi. Meanwhile, new directors were appointed at Mithra Pharmaceuticals and Calliditas Therapeutics.
Pipeline Watch: 12 Approvals And 27 Phase III Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Executives On The Move: Oncorus, Orphazyme and More
Recent executive moves in the industry include C-suite changes at Oncorus and Gamida Cell. Meanwhile, new directors were appointed at Orphazyme and Viatris.
Pipeline Watch: 10 Approvals And Six Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Recent Stories
ASCO 2023 – Novartis’s Adjuvant Breast Cancer Win Comes With Caveats
The Natalee trial hits in all-comers, but an equivocal showing in node-negative patients raises questions about market expansion.
ASCO 2023 – Roche Sees Morpheus And Takes The Red Pill
The company’s TIGIT data are strong enough for a phase 3 trial to be launched, ASCO learns.
ASCO 2023 – Bicara Eyes Head And Neck Niche
Impressive data in HPV-negative disease, potentially beating Keytruda, has the private group making pivotal plans.
ADAURA Survival Boost For AZ’s Tagrisso
Impressive overall survival data from the Phase III ADAURA trial should boost both EGFR testing in non-small cell lung cancer, and sales of the blockbuster NSCLC therapy.
Akero Shows FGF21/GLP-1 Combo’s Potential In NASH And Type 2 Diabetes
Phase IIb data show that Akero’s efruxifermin on top of GLP-1 therapy is relatively safe and offers liver fat reductions and fibrosis improvements in NASH patients with type 2 diabetes.
Allogene May Have Cracked The Off-The-Shelf CAR-T Problem
Allogeneic candidate’s durability is holding up thanks to a novel conditioning regimen, but Phase II data will be crucial test.
AstraZeneca And Daiichi Eyeing Tumor-Agnostic Future For Enhertu?
The ability of Daiichi-Sankyo/AstraZeneca’s blockbuster antibody-drug conjugate Enhertu to tackle a range of HER2-expressing cancers in a Phase II study could lead to a tumor-agnostic future for the product, new data suggest.
China Roundup: Rare Disease Approvals, Local mRNA Shots, CEO Visits
AstraZeneca and CANbridge obtain new approvals for their rare disease drugs in China, where a new domestic mRNA vaccine is also being made available amid a new wave of COVID infections. Meanwhile, the CEOs of pharma and other companies pay visits, showing China remains high on their list of global priorities.
ASCO 2023 – Trop2 Could Validate Merck’s Savvy Deal With Kelun
In Trop2 Merck & Co. might have got itself an ADC at least as good as Gilead and Astra/Daiichi’s leaders, for a fraction of the price.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: a preview of ASCO; Roche CEO on new opportunities; Sanofi sees success in MS; Phase II lupus win for AbbVie; and a Chinese product case study in psoriasis.
ASCO 2023 – Deep And Early Responses Lift Hopes At Effector
New data with a novel RNA translation regulator gave the stock a pre-ASCO boost, but the micro-cap company needs to keep the momentum going.
ASCO 2023 – A Role For Immuno-Oncology In Ovarian Cancer At Last?
AstraZeneca’s Duo-O trial suggests that excluding Brca-positive patients could be the key to Imfinzi’s apparent success in ovarian cancer.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.